Keros Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2015-01-01
- Employees
- 136
- Market Cap
- $1.7B
- Website
- http://www.kerostx.com
- Introduction
Keros Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with unmet medical need. The company was founded in 2015 and is headquartered in Lexington, MA.
The Efficacy and Safety of Elritercept in Adult Participants with Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) with Anemia (RENEW)
- Conditions
- Myelodysplastic Syndromes
- Interventions
- Biological: KER-050Drug: Placebo
- First Posted Date
- 2024-07-12
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- Keros Therapeutics, Inc.
- Target Recruit Count
- 225
- Registration Number
- NCT06499285
- Locations
- 🇺🇸
Study Site 1100, Canton, Ohio, United States
A Study to Investigate the Safety and Efficacy of KER-012 in Combination With Background Therapy in Adult Participants With Pulmonary Arterial Hypertension (PAH) (TROPOS Study).
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Biological: Dose C KER-012Biological: Dose A KER-012Biological: Dose B KER-012Biological: Placebo for 24 Weeks followed by Dose B KER-012 for 72 weeks
- First Posted Date
- 2023-08-04
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- Keros Therapeutics, Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT05975905
- Locations
- 🇺🇸
TROPOS Study Site 111, Scottsdale, Arizona, United States
🇺🇸TROPOS Study Site 107, Tucson, Arizona, United States
🇺🇸Site PI TROPOS Study Site 104, Stanford, California, United States
A Study to Evaluate the Safety and Preliminary Efficacy of a Response-guided Dose Titration of KER-047 in the Treatment of Functional IDA (Iron Deficiency Anemia).
- Conditions
- Iron Deficiency Anemia
- Interventions
- Drug: KER-047
- First Posted Date
- 2023-07-03
- Last Posted Date
- 2023-11-24
- Lead Sponsor
- Keros Therapeutics, Inc.
- Registration Number
- NCT05927012
- Locations
- 🇮🇱
Laniado Hospital - Sanz Medical Center, Netanya, Israel
🇮🇱Hadassah University Medical Center, Jerusalem, Israel
🇮🇱Galilee Medical Center, Nahariya, Israel
Study to Evaluate KER-050 as a Monotherapy or in Combination With Ruxolitinib in Myelofibrosis
- Conditions
- Myelofibrosis
- Interventions
- Drug: KER-050 in combination with ruxolitinibDrug: KER-050 monotherapy
- First Posted Date
- 2021-09-08
- Last Posted Date
- 2022-03-17
- Lead Sponsor
- Keros Therapeutics, Inc.
- Target Recruit Count
- 110
- Registration Number
- NCT05037760
- Locations
- 🇦🇺
The Tweed Hospital, Tweed Heads, New South Wales, Australia
🇦🇺Flinders Medical Centre, Woodville South, South Australia, Australia
🇦🇺Royal Melbourne Hospital, Melbourne, Victoria, Australia
A Study of KER-050 to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes
- Conditions
- Myelodysplastic SyndromesCytopenia
- Interventions
- Drug: KER-050
- First Posted Date
- 2020-06-05
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- Keros Therapeutics, Inc.
- Target Recruit Count
- 140
- Registration Number
- NCT04419649
- Locations
- 🇦🇺
Box Hill Hospital, Box Hill, Victoria, Australia
🇺🇸City of Hope National Medical Center, Duarte, California, United States
🇺🇸University of Pittsburgh Medical Health Center, Pittsburgh, Pennsylvania, United States